{"id":"W2241182848","doi":"10.1182/blood.v110.11.645.645","title":"Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Cohort; Internal medicine; Follicular lymphoma; Adverse effect; Interim analysis; Refractory (planetary science); Gastroenterology; Lymphoma; Progressive disease; Surgery; Oncology; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004741785,0.0007487393,0.001315188,0.000227636,0.000315627,0.0008886784,0.0005155403,0.0009145053,0.001615407],"category_scores_gemma":[0.002171915,0.0003837439,0.001205673,0.0002489053,0.0004300815,0.0006804162,0.0003307371,0.001593546,0.0005341903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006304558,"about_ca_system_score_gemma":0.0008534775,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006842806,"about_ca_topic_score_gemma":0.001011939,"domain_scores_codex":[0.9990584,0.0004760058,0.0000765151,0.0001168434,0.00009756731,0.0001747471],"domain_scores_gemma":[0.9981993,0.0004628658,0.0003626713,0.0001821367,0.0001750775,0.0006180073],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7180897,0.02448946,0.06563396,0.0007127232,0.002878953,0.0008532703,0.0004603274,0.00341523,0.05073152,0.0001811022,0.00668001,0.1258737],"study_design_scores_gemma":[0.2956262,0.5396574,0.144354,0.00005709808,0.002379159,0.0008960599,0.00009591354,0.001659491,0.008516539,0.0002615479,0.006455724,0.00004082722],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910079,0.002478399,0.0007908408,0.0003177512,0.00008330474,0.001388784,0.002164566,0.00006189396,0.001706647],"genre_scores_gemma":[0.9902149,0.0005849338,0.001349562,0.0006828827,0.00009444515,0.001049049,0.005049026,0.00001982712,0.000955348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004741785,"threshold_uncertainty_score":0.02507728,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01971437987032344,"score_gpt":0.3290301285788101,"score_spread":0.3093157487084867,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}